Research Analysts Issue Forecasts for SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Investment analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for Solid Biosciences in a research note issued on Wednesday, February 19th. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn ($1.43) per share for the year, up from their prior estimate of ($2.45). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

SLDB has been the subject of a number of other research reports. JPMorgan Chase & Co. decreased their price objective on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a research note on Friday, January 10th. Truist Financial initiated coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 target price on the stock. Citizens Jmp raised Solid Biosciences to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, JMP Securities initiated coverage on Solid Biosciences in a research note on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 target price on the stock. Nine analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $15.40.

Solid Biosciences Trading Down 7.3 %

SLDB opened at $6.00 on Friday. The stock has a fifty day simple moving average of $3.81 and a two-hundred day simple moving average of $5.78. The company has a market cap of $243.48 million, a price-to-earnings ratio of -1.97 and a beta of 2.01. Solid Biosciences has a 12-month low of $2.88 and a 12-month high of $15.05.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SLDB. Quantum Private Wealth LLC purchased a new position in shares of Solid Biosciences during the 3rd quarter worth about $220,000. Los Angeles Capital Management LLC purchased a new position in shares of Solid Biosciences during the 3rd quarter worth about $293,000. Valence8 US LP purchased a new position in shares of Solid Biosciences during the 3rd quarter worth about $110,000. The Manufacturers Life Insurance Company purchased a new position in shares of Solid Biosciences during the 3rd quarter worth about $71,000. Finally, FMR LLC purchased a new position in shares of Solid Biosciences during the 3rd quarter worth about $305,000. Institutional investors own 81.46% of the company’s stock.

Insider Activity at Solid Biosciences

In other Solid Biosciences news, COO David T. Howton sold 5,072 shares of Solid Biosciences stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $28,403.20. Following the sale, the chief operating officer now owns 15,663 shares of the company’s stock, valued at $87,712.80. The trade was a 24.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jessie Hanrahan sold 4,610 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $25,816.00. Following the completion of the sale, the insider now owns 14,235 shares of the company’s stock, valued at approximately $79,716. This represents a 24.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,069 shares of company stock valued at $137,301. 13.63% of the stock is owned by company insiders.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.